6 results on '"Jennifer E Schuster"'
Search Results
2. Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants
- Author
-
Natasha B, Halasa, Samantha M, Olson, Mary A, Staat, Margaret M, Newhams, Ashley M, Price, Pia S, Pannaraj, Julie A, Boom, Leila C, Sahni, Kathleen, Chiotos, Melissa A, Cameron, Katherine E, Bline, Charlotte V, Hobbs, Aline B, Maddux, Bria M, Coates, Kelly N, Michelson, Sabrina M, Heidemann, Katherine, Irby, Ryan A, Nofziger, Elizabeth H, Mack, Laura, Smallcomb, Stephanie P, Schwartz, Tracie C, Walker, Shira J, Gertz, Jennifer E, Schuster, Satoshi, Kamidani, Keiko M, Tarquinio, Samina S, Bhumbra, Mia, Maamari, Janet R, Hume, Hillary, Crandall, Emily R, Levy, Matt S, Zinter, Tamara T, Bradford, Heidi R, Flori, Melissa L, Cullimore, Michele, Kong, Natalie Z, Cvijanovich, Suzanne M, Gilboa, Kara N, Polen, Angela P, Campbell, Adrienne G, Randolph, and Manish M, Patel
- Subjects
Vaccines, Synthetic ,COVID-19 Vaccines ,SARS-CoV-2 ,Vaccination ,COVID-19 ,Infant ,Mothers ,Obstetrics and Gynecology ,General Medicine ,Hospitalization ,Pregnancy ,Humans ,Female ,mRNA Vaccines ,Pregnancy Complications, Infectious - Abstract
Infants younger than 6 months of age are at high risk for complications of coronavirus disease 2019 (Covid-19) and are not eligible for vaccination. Transplacental transfer of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after maternal Covid-19 vaccination may confer protection against Covid-19 in infants.We used a case-control test-negative design to assess the effectiveness of maternal vaccination during pregnancy against hospitalization for Covid-19 among infants younger than 6 months of age. Between July 1, 2021, and March 8, 2022, we enrolled infants hospitalized for Covid-19 (case infants) and infants hospitalized without Covid-19 (control infants) at 30 hospitals in 22 states. We estimated vaccine effectiveness by comparing the odds of full maternal vaccination (two doses of mRNA vaccine) among case infants and control infants during circulation of the B.1.617.2 (delta) variant (July 1, 2021, to December 18, 2021) and the B.1.1.259 (omicron) variant (December 19, 2021, to March 8, 2022).A total of 537 case infants (181 of whom had been admitted to a hospital during the delta period and 356 during the omicron period; median age, 2 months) and 512 control infants were enrolled and included in the analyses; 16% of the case infants and 29% of the control infants had been born to mothers who had been fully vaccinated against Covid-19 during pregnancy. Among the case infants, 113 (21%) received intensive care (64 [12%] received mechanical ventilation or vasoactive infusions). Two case infants died from Covid-19; neither infant's mother had been vaccinated during pregnancy. The effectiveness of maternal vaccination against hospitalization for Covid-19 among infants was 52% (95% confidence interval [CI], 33 to 65) overall, 80% (95% CI, 60 to 90) during the delta period, and 38% (95% CI, 8 to 58) during the omicron period. Effectiveness was 69% (95% CI, 50 to 80) when maternal vaccination occurred after 20 weeks of pregnancy and 38% (95% CI, 3 to 60) during the first 20 weeks of pregnancy.Maternal vaccination with two doses of mRNA vaccine was associated with a reduced risk of hospitalization for Covid-19, including for critical illness, among infants younger than 6 months of age. (Funded by the Centers for Disease Control and Prevention.).
- Published
- 2022
- Full Text
- View/download PDF
3. BNT162b2 Protection against the Omicron Variant in Children and Adolescents
- Author
-
Ashley M, Price, Samantha M, Olson, Margaret M, Newhams, Natasha B, Halasa, Julie A, Boom, Leila C, Sahni, Pia S, Pannaraj, Katherine, Irby, Katherine E, Bline, Aline B, Maddux, Ryan A, Nofziger, Melissa A, Cameron, Tracie C, Walker, Stephanie P, Schwartz, Elizabeth H, Mack, Laura, Smallcomb, Jennifer E, Schuster, Charlotte V, Hobbs, Satoshi, Kamidani, Keiko M, Tarquinio, Tamara T, Bradford, Emily R, Levy, Kathleen, Chiotos, Samina S, Bhumbra, Natalie Z, Cvijanovich, Sabrina M, Heidemann, Melissa L, Cullimore, Shira J, Gertz, Bria M, Coates, Mary A, Staat, Matt S, Zinter, Michele, Kong, Brandon M, Chatani, Janet R, Hume, Katri V, Typpo, Mia, Maamari, Heidi R, Flori, Mark W, Tenforde, Laura D, Zambrano, Angela P, Campbell, Manish M, Patel, and Adrienne G, Randolph
- Subjects
Vaccines, Synthetic ,COVID-19 Vaccines ,Adolescent ,SARS-CoV-2 ,Critical Illness ,COVID-19 ,Vaccine Efficacy ,General Medicine ,Hospitalization ,Case-Control Studies ,Child, Preschool ,Humans ,mRNA Vaccines ,Child ,BNT162 Vaccine - Abstract
Spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 (omicron) variant, which led to increased U.S. hospitalizations for coronavirus disease 2019 (Covid-19), generated concern about immune evasion and the duration of protection from vaccines in children and adolescents.Using a case-control, test-negative design, we assessed vaccine effectiveness against laboratory-confirmed Covid-19 leading to hospitalization and against critical Covid-19 (i.e., leading to receipt of life support or to death). From July 1, 2021, to February 17, 2022, we enrolled case patients with Covid-19 and controls without Covid-19 at 31 hospitals in 23 states. We estimated vaccine effectiveness by comparing the odds of antecedent full vaccination (two doses of BNT162b2 messenger RNA vaccine) at least 14 days before illness among case patients and controls, according to time since vaccination for patients 12 to 18 years of age and in periods coinciding with circulation of B.1.617.2 (delta) (July 1, 2021, to December 18, 2021) and omicron (December 19, 2021, to February 17, 2022) among patients 5 to 11 and 12 to 18 years of age.We enrolled 1185 case patients (1043 [88%] of whom were unvaccinated, 291 [25%] of whom received life support, and 14 of whom died) and 1627 controls. During the delta-predominant period, vaccine effectiveness against hospitalization for Covid-19 among adolescents 12 to 18 years of age was 93% (95% confidence interval [CI], 89 to 95) 2 to 22 weeks after vaccination and was 92% (95% CI, 80 to 97) at 23 to 44 weeks. Among adolescents 12 to 18 years of age (median interval since vaccination, 162 days) during the omicron-predominant period, vaccine effectiveness was 40% (95% CI, 9 to 60) against hospitalization for Covid-19, 79% (95% CI, 51 to 91) against critical Covid-19, and 20% (95% CI, -25 to 49) against noncritical Covid-19. During the omicron period, vaccine effectiveness against hospitalization among children 5 to 11 years of age was 68% (95% CI, 42 to 82; median interval since vaccination, 34 days).BNT162b2 vaccination reduced the risk of omicron-associated hospitalization by two thirds among children 5 to 11 years of age. Although two doses provided lower protection against omicron-associated hospitalization than against delta-associated hospitalization among adolescents 12 to 18 years of age, vaccination prevented critical illness caused by either variant. (Funded by the Centers for Disease Control and Prevention.).
- Published
- 2022
- Full Text
- View/download PDF
4. Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents
- Author
-
Samantha M, Olson, Margaret M, Newhams, Natasha B, Halasa, Ashley M, Price, Julie A, Boom, Leila C, Sahni, Pia S, Pannaraj, Katherine, Irby, Tracie C, Walker, Stephanie P, Schwartz, Aline B, Maddux, Elizabeth H, Mack, Tamara T, Bradford, Jennifer E, Schuster, Ryan A, Nofziger, Melissa A, Cameron, Kathleen, Chiotos, Melissa L, Cullimore, Shira J, Gertz, Emily R, Levy, Michele, Kong, Natalie Z, Cvijanovich, Mary A, Staat, Satoshi, Kamidani, Brandon M, Chatani, Samina S, Bhumbra, Katherine E, Bline, Mary G, Gaspers, Charlotte V, Hobbs, Sabrina M, Heidemann, Mia, Maamari, Heidi R, Flori, Janet R, Hume, Matt S, Zinter, Kelly N, Michelson, Laura D, Zambrano, Angela P, Campbell, Manish M, Patel, and Adrienne G, Randolph
- Subjects
Male ,COVID-19 Vaccines ,Adolescent ,SARS-CoV-2 ,Immunization, Secondary ,Patient Acuity ,COVID-19 ,Vaccine Efficacy ,General Medicine ,United States ,Hospitalization ,Life Support Care ,Intensive Care Units ,COVID-19 Testing ,Editorial ,Case-Control Studies ,Humans ,Female ,Child ,BNT162 Vaccine - Abstract
The increasing incidence of pediatric hospitalizations associated with coronavirus disease 2019 (Covid-19) caused by the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the United States has offered an opportunity to assess the real-world effectiveness of the BNT162b2 messenger RNA vaccine in adolescents between 12 and 18 years of age.We used a case-control, test-negative design to assess vaccine effectiveness against Covid-19 resulting in hospitalization, admission to an intensive care unit (ICU), the use of life-supporting interventions (mechanical ventilation, vasopressors, and extracorporeal membrane oxygenation), or death. Between July 1 and October 25, 2021, we screened admission logs for eligible case patients with laboratory-confirmed Covid-19 at 31 hospitals in 23 states. We estimated vaccine effectiveness by comparing the odds of antecedent full vaccination (two doses of BNT162b2) in case patients as compared with two hospital-based control groups: patients who had Covid-19-like symptoms but negative results on testing for SARS-CoV-2 (test-negative) and patients who did not have Covid-19-like symptoms (syndrome-negative).A total of 445 case patients and 777 controls were enrolled. Overall, 17 case patients (4%) and 282 controls (36%) had been fully vaccinated. Of the case patients, 180 (40%) were admitted to the ICU, and 127 (29%) required life support; only 2 patients in the ICU had been fully vaccinated. The overall effectiveness of the BNT162b2 vaccine against hospitalization for Covid-19 was 94% (95% confidence interval [CI], 90 to 96); the effectiveness was 95% (95% CI, 91 to 97) among test-negative controls and 94% (95% CI, 89 to 96) among syndrome-negative controls. The effectiveness was 98% against ICU admission and 98% against Covid-19 resulting in the receipt of life support. All 7 deaths occurred in patients who were unvaccinated.Among hospitalized adolescent patients, two doses of the BNT162b2 vaccine were highly effective against Covid-19-related hospitalization and ICU admission or the receipt of life support. (Funded by the Centers for Disease Control and Prevention.).
- Published
- 2022
- Full Text
- View/download PDF
5. Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes
- Author
-
Nancy Murray, Jane W. Newburger, Janet R. Hume, Stephanie P Schwartz, Charlotte V. Hobbs, Leora R. Feldstein, Katharine N. Clouser, Vijaya L. Soma, Tamara T. Bradford, Mark W. Hall, Julie C. Fitzgerald, Steven M. Horwitz, Michele Kong, Laura L. Loftis, Gwenn E. McLaughlin, Christopher L. Carroll, Lincoln S. Smith, Mary Beth F. Son, Charles E. Rose, Sule Doymaz, Margaret M. Newhams, Sabrina M. Heidemann, John S. Giuliano, Elizabeth H. Mack, Christopher J. Babbitt, Natalie Z. Cvijanovich, Phoebe H. Yager, Aalok R. Singh, Katherine Irby, Cameron C. Young, Adrienne G. Randolph, Mia Maamari, Vicki L. Montgomery, Natasha B. Halasa, Kevin G. Friedman, Becky J. Riggs, Manish M. Patel, Bria M. Coates, Aline B Maddux, Keiko M. Tarquinio, Michael A. Keenaghan, Courtney M. Rowan, and Jennifer E. Schuster
- Subjects
Biological Products ,Pediatrics ,medicine.medical_specialty ,2019-20 coronavirus outbreak ,business.industry ,Immunoglobulins, Intravenous ,General Medicine ,medicine.disease ,Combination drug therapy ,Systemic inflammatory response syndrome ,Pharmacotherapy ,otorhinolaryngologic diseases ,Humans ,Immunologic Factors ,Medicine ,Combined Modality Therapy ,Original Article ,Immunotherapy ,Young adult ,business ,Initial therapy ,Glucocorticoids ,Cohort study - Abstract
Background The assessment of real-world effectiveness of immunomodulatory medications for multisystem inflammatory syndrome in children (MIS-C) may guide therapy. Methods We analyzed surveillance data on inpatients younger than 21 years of age who had MIS-C and were admitted to 1 of 58 U.S. hospitals between March 15 and October 31, 2020. The effectiveness of initial immunomodulatory therapy (day 0, indicating the first day any such therapy for MIS-C was given) with intravenous immune globulin (IVIG) plus glucocorticoids, as compared with IVIG alone, was evaluated with propensity-score matching and inverse probability weighting, with adjustment for baseline MIS-C severity and demographic characteristics. The primary outcome was cardiovascular dysfunction (a composite of left ventricular dysfunction or shock resulting in the use of vasopressors) on or after day 2. Secondary outcomes included the components of the primary outcome, the receipt of adjunctive treatment (glucocorticoids in patients not already receiving glucocorticoids on day 0, a biologic, or a second dose of IVIG) on or after day 1, and persistent or recurrent fever on or after day 2. Results A total of 518 patients with MIS-C (median age, 8.7 years) received at least one immunomodulatory therapy; 75% had been previously healthy, and 9 died. In the propensity-score–matched analysis, initial treatment with IVIG plus glucocorticoids (103 patients) was associated with a lower risk of cardiovascular dysfunction on or after day 2 than IVIG alone (103 patients) (17% vs. 31%; risk ratio, 0.56; 95% confidence interval [CI], 0.34 to 0.94). The risks of the components of the composite outcome were also lower among those who received IVIG plus glucocorticoids: left ventricular dysfunction occurred in 8% and 17% of the patients, respectively (risk ratio, 0.46; 95% CI, 0.19 to 1.15), and shock resulting in vasopressor use in 13% and 24% (risk ratio, 0.54; 95% CI, 0.29 to 1.00). The use of adjunctive therapy was lower among patients who received IVIG plus glucocorticoids than among those who received IVIG alone (34% vs. 70%; risk ratio, 0.49; 95% CI, 0.36 to 0.65), but the risk of fever was unaffected (31% and 40%, respectively; risk ratio, 0.78; 95% CI, 0.53 to 1.13). The inverse-probability-weighted analysis confirmed the results of the propensity-score–matched analysis. Conclusions Among children and adolescents with MIS-C, initial treatment with IVIG plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone. (Funded by the Centers for Disease Control and Prevention.)
- Published
- 2021
- Full Text
- View/download PDF
6. Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine
- Author
-
Todd Bradley, Daniel Louiselle, Cas LeMaster, Rangaraj Selvarangan, Elin Grundberg, Tomi Pastinen, Angela L. Myers, Dithi Banerjee, Bradley Belden, Elizabeth Fraley, Rebecca Biswell, Jennifer E. Schuster, and Nick Nolte
- Subjects
2019-20 coronavirus outbreak ,COVID-19 Vaccines ,viruses ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,030204 cardiovascular system & hematology ,Antibodies, Viral ,COVID-19 Serological Testing ,03 medical and health sciences ,0302 clinical medicine ,Immunogenicity, Vaccine ,Correspondence ,Medicine ,Humans ,030212 general & internal medicine ,skin and connective tissue diseases ,Vaccine Potency ,BNT162 Vaccine ,Messenger RNA ,biology ,business.industry ,SARS-CoV-2 ,Immunogenicity ,fungi ,General Medicine ,biochemical phenomena, metabolism, and nutrition ,Virology ,Antibodies, Neutralizing ,body regions ,Antibody response ,Immunization ,Immunoglobulin G ,Spike Glycoprotein, Coronavirus ,biology.protein ,Antibody ,business - Abstract
Antibody Responses after a Single Dose of SARS-CoV-2 Vaccine Reported results of immunization with SARS-CoV-2 vaccine have focused on two doses given to seronegative persons. In a small study invol...
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.